DEFM14A: Checkpoint Therapeutics Stockholders to Vote on Merger with Sun Pharmaceutical Industries

Checkpoint Therapeutics is holding a special meeting on May 28, 2025, for stockholders to vote on the proposed merger with Sun Pharmaceutical Industries, Inc.

Summary

• Checkpoint Therapeutics is holding a special meeting of stockholders on May 28, 2025, to vote on the proposed merger with Sun Pharmaceutical Industries, Inc.
• The merger agreement, dated March 9, 2025, and amended on April 14, 2025, involves Sun Pharmaceutical Industries acquiring Checkpoint Therapeutics.
• Stockholders will receive $4.10 in cash and one contingent value right (CVR) for each share of common stock owned.
• The CVR represents the right to receive a contingent cash payment of up to $0.70 upon achieving a specified milestone.
• The Checkpoint Board recommends voting FOR the merger proposal, the compensation proposal, and the adjournment proposal.
• Fortress Biotech, Inc., which owns approximately 8.0% of the outstanding shares, has agreed to vote in favor of the merger.
• The merger requires approval by a majority of votes cast by unaffiliated stockholders and a majority in voting power of outstanding shares.
• The transaction is subject to regulatory approvals, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Act.
• The merger is expected to close in the second quarter of 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The merger provides a premium for stockholders, but the CVR adds uncertainty. The board's recommendation and Fortress's support are positive signals.

Positives

• Stockholders will receive $4.10 in cash per share, representing a premium to the recent trading price.
• The CVR provides an opportunity for additional payment of up to $0.70 per share.
• The Checkpoint Board and Special Committee unanimously support the merger.
• Fortress Biotech, Inc., a major stockholder, has committed to voting in favor of the merger.
• The merger provides liquidity and certainty of value to Checkpoint stockholders.

Negatives

• The CVR payment is contingent and may not be realized.
• The merger will result in Checkpoint Therapeutics ceasing to be a publicly traded company.
• Stockholders will not participate in any potential future earnings or growth of Checkpoint Therapeutics, except through the CVR.
• The exchange of shares for cash and CVRs will be a taxable transaction for U.S. federal income tax purposes.

Risks

• The merger is subject to regulatory approvals, and there is a risk that these approvals may not be obtained or may involve burdensome conditions.
• There is a risk that the merger may not be completed for other reasons, such as failure to obtain stockholder approval.
• The CVR payment is contingent on achieving a specific regulatory milestone, and there is no guarantee that this milestone will be met.
• The value of the CVRs is uncertain, and stockholders may not receive any payment beyond the initial cash consideration.
• The loss of key management or other personnel of Checkpoint Therapeutics during the pendency of the Merger.

Future Outlook

The merger is expected to close in the second quarter of 2025, subject to stockholder and regulatory approvals.

Management Comments

• The Checkpoint Board (acting on the recommendation of the Special Committee), by unanimous vote of Checkpoints directors, recommends that you vote: (1) FOR the Merger Proposal; (2) FOR the Compensation Proposal; and (3) FOR the Adjournment Proposal.

Industry Context

The announcement reflects ongoing consolidation trends in the pharmaceutical industry, with larger companies acquiring smaller firms to expand their product portfolios and pipelines.

Comparison to Industry Standards

• The Common Cash Amount represents an approximately 66% premium to the closing price of the Common Stock of $2.47 per share on March 7, 2025.
• The Common Cash Amount represents an approximately 35% premium to the 30-day trading period volume weighted average price (VWAP) of the Common Stock as of March 7, 2025.
• The Common Cash Amount represents an approximately 21% premium to the 60-day trading period VWAP of the Common Stock as of March 7, 2025.

Legal Proceedings

• As of the date of this proxy statement, there are no legal proceedings challenging the Merger.
• As of the date of this proxy statement, Checkpoint has received 2 demand letters from purported Checkpoint stockholders generally alleging disclosure deficiencies in connection with the disclosures associated with the Transactions.

Related Party Transactions

• Concurrently with the execution of the Merger Agreement, Checkpoint entered into a Royalty Agreement with Parent and Fortress pursuant to which following, and subject to the occurrence of, the Effective Time, Fortress will receive a royalty interest right based on worldwide net sales of UNLOXCYTTM and certain related products of Checkpoint and Parent.
• Pursuant to the Merger Agreement, at or prior to the Closing, Checkpoint and Fortress will enter into a Transition Services Agreement, pursuant to which, from and after the Effective Time, Fortress would provide the Company with certain transition services as set forth in the Transition Services Agreement, including certain back-office support and services, for the period of time and in exchange for compensation calculated at specified hourly rates, as set forth therein.

Stakeholder Impact

• Shareholders will receive $4.10 per share in cash and one CVR, potentially worth up to $0.70.
• Employees may experience changes in their roles and responsibilities following the merger.
• Customers and suppliers may see changes in the company's operations and product offerings.

Next Steps

• The Company Stockholders will vote on the Merger Proposal, the Compensation Proposal, and the Adjournment Proposal at the Special Meeting on May 28, 2025.
• The Company, Parent and Merger Sub will seek regulatory approvals, including HSR Act clearance.
• The parties will work to satisfy the closing conditions outlined in the Merger Agreement.

Key Dates

Keywords

merger, checkpoint therapeutics, sun pharmaceutical industries, stockholders, cvr, acquisition, fortress biotech, unloxcyt, shares, agreement